Join
Live feed
·
PRReleasevia Quantisnow
Syros Pharmaceuticals Inc. logo

Syros Presents New Data from Phase 1 Trial of SY-5609 and Details Three-Pronged Combination Strategy to Advance SY-5609 in Solid Tumors and Blood Cancer

ByQuantisnow·Wall Street's wire, on your screen.
SYRS· Syros Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SYRS (Syros Pharmaceuticals Inc.) and more on Quantisnow.